Role of biotransformation studies in minimizing metabolism-related liabilities in drug discovery

AAPS Journal

Volumn 10, Issue 1, 2008, Pages 178-192

  Shu, Yue Zhong ^a   Johnson, Benjamin M ^a   Yang, Tian J ^b  

^a BRISTOL MYERS SQUIBB   (United States)

^b HOFFMANN LA ROCHE INC   (United States)

Author keywords

Bioactivation; Biotransformation; CYP; Drug discovery; Glutathione; Metabolism

Indexed keywords

ACYLGLUCURONIDE; ALKENE DERIVATIVE; AMINE; AROMATIC COMPOUND; CYTOCHROME; DIHYDROPYRIDINE; GLUCURONIDE; GLUTATHIONE; HETEROCYCLIC COMPOUND; N BENZYLCYCLOPROPYLAMINE; PYRROLIZIDINE ALKALOID; SITAGLIPTIN; TERTIARY AMINE;

CANNULATION; CARCINOGENICITY; CHEMICAL CARCINOGENESIS; CHEMICAL MODIFICATION; COMPUTER MODEL; COVALENT BOND; DNA ADDUCT; DNA MODIFICATION; DRUG ABSORPTION; DRUG ANALYSIS; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG METABOLISM; DRUG RESEARCH; DRUG TRANSFORMATION; ENZYME INACTIVATION; ENZYME INHIBITION; GENOTOXICITY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIVER TOXICITY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NEPHROTOXICITY; NONHUMAN; REVIEW; RNA INTERFERENCE; STRUCTURE ANALYSIS; TOXICITY TESTING;

ANIMALS; BIOMEDICAL RESEARCH; BIOTRANSFORMATION; DRUG DESIGN; HUMANS; PHARMACEUTICAL PREPARATIONS; TECHNOLOGY, PHARMACEUTICAL;

EID: 51249100615     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-008-9016-9     Document Type: Review

References (105)

1. I. Kola, and J. Landis. Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 3:711-715 (2004).
2. A. E. Nassar, A. M. Kamel, and C. Clarimont. Improving the decision-making process in structural modification of drug candidates: reducing toxicity. Drug Discov. Today. 9:1055-1064 (2004).
3. A. S. Kalgutkar, I. Gardner, R. S. Obach, et al. A comprehensive listing of bioactivation pathways of organic functional groups. Curr. Drug Metab. 6:161-225 (2005).
4. K. Park, D. P. Williams, D. J. Naisbitt, N. R. Kitteringham, and M. Pirmohamed. Investigation of toxic metabolites during drug development. Toxicol. Appl. Pharmacol. 207:425-434 (2005).
5. R. J. Riley, K. Grime, and R. Weaver. Time-dependent CYP inhibition. Expert. Opin. Drug Metab. Toxicol. 3:51-66 (2007).
6. R. Silverman. Mechanism-based Enzyme Inactivation, CRC Press, Boca Raton, FL, USA, 1998.
7. F. Ghanbari, K. Rowland-Yeo, J. C. Bloomer, et al. A critical evaluation of the experimental design of studies of mechanism based enzyme inhibition, with implications for in vitro - in vivo extrapolation. Curr. Drug Metab. 7:315-334 (2006).
8. R. S. Obach, R. L. Walsky, and K. Venkatakrishnan. Mechanism-based inactivation of human cytochrome p450 enzymes and the prediction of drug-drug interactions. Drug Metab. Dispos. 35:246-255 (2007).
9. K. Venkatakrishnan, and R. S. Obach. Drug-drug interactions via mechanism-based cytochrome P450 inactivation: Points to consider for risk assessment from in vitro data and clinical pharmacologic evaluation. Curr. Drug Metab. 8:449-462 (2007).
10. J. Uetrecht. Idiosyncratic drug reactions: Current understanding. Annu. Rev. Pharmacol. Toxicol. 47:513-539 (2007).
11. J. M. Shenton, M. Teranishi, M. S. Abu-Asab, J. A. Yager, and J. P. Uetrecht. Characterization of a potential animal model of an idiosyncratic drug reaction: Nevirapine-induced skin rash in the rat. Chem. Res. Toxicol. 16:1078-1089 (2003).
12. W. Lu, and J. P. Uetrecht. Possible bioactivation pathways of lamotrigine. Drug Metab. Dispos. 35:1050-1056 (2007).
13. J. Uetrecht. Evaluation of which reactive metabolite, if any, is responsible for a specific idiosyncratic reaction. Drug Metab. Rev. 38:745-753 (2006).
14. J. L. Bolton, M. A. Trush, T. M. Penning, G. Dryhurst, and T. J. Monks. Role of quinones in toxicology. Chem. Res. Toxicol. 13:135-160 (2000).
15. D. C. Thompson, K. Perera, E. S. Krol, and J. L. Bolton. o-Methoxy-4-alkylphenols that form quinone methides of intermediate reactivity are the most toxic in rat liver slices. Chem. Res. Toxicol. 8:323-327 (1995).
16. J. N. Commandeur, G. J. Stijntjes, and N. P. Vermeulen. Enzymes and transport systems involved in the formation and disposition of glutathione S-conjugates. Role in bioactivation and detoxication mechanisms of xenobiotics. Pharmacol. Rev. 47:271-330 (1995).
17. W. G. Humphreys, and S. E. Unger. Safety assessment of drug metabolites: Characterization of chemically stable metabolites. Chem. Res. Toxicol. 19:1564-1569 (2006).
18. T. A. Baillie, P. G. Pearson, M. S. Rashed, and W. N. Howald. The use of mass spectrometry in the study of chemically-reactive drug metabolites. Application of MS/MS and LC/MS to the analysis of glutathione- and related S-linked conjugates of N-methylformamide. J. Pharm. Biomed. Anal. 7:1351-1360 (1989).
19. B. M. Johnson, S. X. Qiu, S. Zhang, et al. Identification of novel electrophilic metabolites of piper methysticum Forst (Kava). Chem. Res. Toxicol. 16:733-740 (2003).
20. J. Gan, T. W. Harper, M. M. Hsueh, Q. Qu, and W. G. Humphreys. Dansyl glutathione as a trapping agent for the quantitative estimation and identification of reactive metabolites. Chem. Res. Toxicol. 18:896-903 (2005).
21. J. R. Soglia, S. P. Harriman, S. Zhao, et al. The development of a higher throughput reactive intermediate screening assay incorporating micro-bore liquid chromatography-micro-electrospray ionization-tandem mass spectrometry and glutathione ethyl ester as an in vitro conjugating agent. J. Pharm. Biomed. Anal. 36:105-116 (2004).
22. A. Mutlib, W. Lam, J. Atherton, H. Chen, P. Galatsis, and W. Stolle. Application of stable isotope labeled glutathione and rapid scanning mass spectrometers in detecting and characterizing reactive metabolites. Rapid Commun. Mass Spectrom. 19:3482-3492 (2005).
23. J. W. Gorrod, and G. Aislaitner. The metabolism of alicyclic amines to reactive iminium ion intermediates. Eur. J. Drug Metab. Pharmacokinet. 19:209-217 (1994).
24. N. Masubuchi, C. Makino, and N. Murayama. Prediction of in vivo potential for metabolic activation of drugs into chemically reactive intermediate: Correlation of in vitro and in vivo generation of reactive intermediates and in vitro glutathione conjugate formation in rats and humans. Chem. Res. Toxicol. 20:455-464 (2007).
25. D. C. Evans, A. P. Watt, D. A. Nicoll-Griffith, and T. A. Baillie. Drug-protein adducts: An industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. Chem. Res. Toxicol. 17:3-16 (2004).
26. A. S. Kalgutkar, R. S. Obach, and T. S. Maurer. Mechanism-based inactivation of cytochrome P450 enzymes: Chemical mechanisms, structure-activity relationships and relationship to clinical drug-drug interactions and idiosyncratic adverse drug reactions. Curr. Drug Metab. 8:407-447 (2007).
27. D. R. Jones, J. C. Gorski, M. A. Hamman, B. S. Mayhew, S. Rider, and S. D. Hall. Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation. J. Pharmacol. Exp. Ther. 290:1116-1125 (1999).
28. E. Fontana, P. M. Dansette, and S. M. Poli. Cytochrome p450 enzymes mechanism based inhibitors: Common sub-structures and reactivity. Curr. Drug Metab. 6:413-454 (2005).
29. H. L. Lin, U. M. Kent, and P. F. Hollenberg. Mechanism-based inactivation of cytochrome P450 3A4 by 17 alpha-ethynylestradiol: evidence for heme destruction and covalent binding to protein. J. Pharmacol. Exp. Ther. 301:160-167 (2002).
30. B. S. Mayhew, D. R. Jones, and S. D. Hall. An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation. Drug Metab. Dispos. 28:1031-1037 (2000).
31. C. S. Ernest 2nd, S. D. Hall, and D. R. Jones. Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J. Pharmacol. Exp. Ther. 312:583-591 (2005).
32. B. Ma, T. Prueksaritanont, and J. H. Lin. Drug interactions with calcium channel blockers: Possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab. Dispos. 28:125-130 (2000).
33. O. M. Bakke, W. M. Wardell, and L. Lasagna. Drug discontinuations in the United Kingdom and the United States, 1964 to 1983: Issues of safety. Clin. Pharmacol. Ther. 35:559-567 (1984).
34. J. Wang, M. Davis, F. Li, F. Azam, J. Scatina, and R. Talaat. A novel approach for predicting acyl glucuronide reactivity via Schiff base formation: Development of rapidly formed peptide adducts for LC/MS/MS measurements. Chem. Res. Toxicol. 17:1206-1216 (2004).
35. G. S. Walker, J. Atherton, J. Bauman, et al. Determination of degradation pathways and kinetics of acyl glucuronides by NMR spectroscopy. Chem. Res. Toxicol. 20:876-886 (2007).
36. E. Skordi, I. D. Wilson, J. C. Lindon, and J. K. Nicholson. Kinetic studies on the intramolecular acyl migration of beta-1-O-acyl glucuronides: Application to the glucuronides of (R)- and (S)-ketoprofen, (R)- and (S)-hydroxy-ketoprofen metabolites, and tolmetin by 1H-NMR spectroscopy. Xenobiotica. 35:715-725 (2005).
37. S. J. Vanderhoeven, J. C. Lindon, J. Troke, J. K. Nicholson, and I. D. Wilson. NMR spectroscopic studies of the transacylation reactivity of ibuprofen 1-beta-O-acyl glucuronide. J. Pharm. Biomed. Anal. 41:1002-1006 (2006).
38. M. R. Anari, R. I. Sanchez, R. Bakhtiar, R. B. Franklin, and T. A. Baillie. Integration of knowledge-based metabolic predictions with liquid chromatography data-dependent tandem mass spectrometry for drug metabolism studies: Application to studies on the biotransformation of indinavir. Anal. Chem. 76:823-832 (2004).
39. A. Rostami-Hodjegan, and G. T. Tucker. Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat. Rev. Drug Discov. 6:140-148 (2007).
40. J. C. Madden, and M. T. Cronin. Structure-based methods for the prediction of drug metabolism. Expert. Opin. Drug Metab. Toxicol. 2:545-557 (2006).
41. S. Ekins, S. Andreyev, A. Ryabov, et al. Computational prediction of human drug metabolism. Expert. Opin. Drug Metab. Toxicol. 1:303-324 (2005).
42. S. S. De Buck, V. K. Sinha, L. A. Fenu, R. A. Gilissen, C. E. Mackie, and M. J. Nijsen. The prediction of drug metabolism, tissue distribution, and bioavailability of 50 structurally diverse compounds in rat using mechanism-based absorption, distribution, and metabolism prediction tools. Drug Metab. Dispos. 35:649-659 (2007).
43. G. Cruciani, E. Carosati, B. De Boeck, et al. MetaSite: Understanding metabolism in human cytochromes from the perspective of the chemist. J. Med. Chem. 48:6970-6979 (2005).
44. R. P. Sheridan, K. R. Korzekwa, R. A. Torres, and M. J. Walker. Empirical regioselectivity models for human cytochromes P450 3A4, 2D6, and 2C9. J. Med. Chem. 50:3173-3184 (2007).
45. J. Langowski, and A. Long. Computer systems for the prediction of xenobiotic metabolism. Adv. Drug Deliv. Rev. 54:407-415 (2002).
46. P. R. Ortiz de Montellano, and J. M. Matthews. Autocatalytic alkylation of the cytochrome P-450 prosthetic haem group by 1-aminobenzotriazole. Isolation of an NN-bridged benzyne-protoporphyrin IX adduct. Biochem. J. 195:761-764 (1981).
47. S. K. Balani, T. Zhu, T. J. Yang, Z. Liu, B. He, and F. W. Lee. Effective dosing regimen of 1-aminobenzotriazole for inhibition of antipyrine clearance in rats, dogs, and monkeys. Drug Metab. Dispos. 30:1059-1062 (2002).
48. S. K. Balani, P. Li, J. Nguyen, et al. Effective dosing regimen of 1-aminobenzotriazole for inhibition of antipyrine clearance in guinea pigs and mice using serial sampling. Drug Metab. Dispos. 32:1092-1095 (2004).
49. D. P. Williams, D. J. Antoine, P. J. Butler, et al. The metabolism and toxicity of furosemide in the wistar rat and CD-1 mouse: A chemical and biochemical definition of the toxicophore. J. Pharmacol. Exp. Ther. 322:1208-1220 (2007).
50. C. M. Henesey, and P. J. Harvison. Renal damage, metabolism and covalent binding following administration of the nephrotoxicant N-(3,5-dichlorophenyl)succinimide (NDPS) to male Fischer 344 rats. Toxicology. 170:187-200 (2002).
51. K. L. Davis-Bruno, and A. Atrakchi. A regulatory perspective on issues and approaches in characterizing human metabolites. Chem. Res. Toxicol. 19:1561-1563 (2006).
52. W. Li, D. Zhang, L. Wang, et al. Biotransformation of carbon-14-labeled muraglitazar in male mice: Interspecies difference in metabolic pathways leading to unique metabolites. Drug Metab. Dispos. 34:807-820 (2006).
53. K. Matsui, M. Mishima, Y. Nagai, T. Yuzuriha, and T. Yoshimura. Absorption, distribution, metabolism, and excretion of donepezil (Aricept) after a single oral administration to Rat. Drug Metab. Dispos. 27:1406-1414 (1999).
54. S. J. Roffey, R. S. Obach, J. I. Gedge, and D. A. Smith. What is the objective of the mass balance study? A retrospective analysis of data in animal and human excretion studies employing radiolabeled drugs. Drug Metab. Rev. 39:17-43 (2007).
55. D. Pereg, N. Tampal, P. Espandiari, and L. W. Robertson. Distribution and macromolecular binding of benzo[a]pyrene and two polychlorinated biphenyl congeners in female mice. Chem. Biol. Interact. 137:243-258 (2001).
56. Y. Hsieh, J. Chen, and W. A. Korfmacher. Mapping pharmaceuticals in tissues using MALDI imaging mass spectrometry. J. Pharmacol. Toxicol. Methods. 55:193-200 (2007).
57. M. L. Reyzer, Y. Hsieh, K. Ng, W. A. Korfmacher, and R. M. Caprioli. Direct analysis of drug candidates in tissue by matrix-assisted laser desorption/ionization mass spectrometry. J. Mass Spectrom. 38:1081-1092 (2003).
58. M. L. Reyzer, and R. M. Caprioli. MALDI-MS-based imaging of small molecules and proteins in tissues. Feb. Curr. Opin. Chem. Biol. 11:29-35 (2007).
59. A. M. Yu. Small interfering RNA in drug metabolism and transport. Curr. Drug Metab. 8:700-708 (2007).
60. T. M. Fountaine, and R. Wade-Martins. RNA interference-mediated knockdown of alpha-synuclein protects human dopaminergic neuroblastoma cells from MPP(+) toxicity and reduces dopamine transport. J. Neurosci. Res. 85:351-363 (2007).
61. F. J. Gonzalez. CYP3A4 and pregnane X receptor humanized mice. J. Biochem. Mol. Toxicol. 21:158-162 (2007).
62. F. J. Gonzalez, and A. M. Yu. Cytochrome P450 and xenobiotic receptor humanized mice. Annu. Rev. Pharmacol. Toxicol. 46:41-64 (2006).
63. F. P. Guengerich. Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. Chem. Res. Toxicol. 14:611-650 (2001).
64. N. Castagnoli Jr., J. M. Rimoldi, J. Bloomquist, and K. P. Castagnoli. Potential metabolic bioactivation pathways involving cyclic tertiary amines and azaarenes. Chem. Res. Toxicol. 10:924-940 (1997).
65. B. M. Moore, F. C. Seaman, R. T. Wheelhouse, and L. Hurley. Mechanism for the catalytic activation of ecteinascidin 743 and its subsequent alkylation of guanine N2. J. Am. Chem. Soc. 120:2490-2491 (1998).
66. G. C. Hill, T. P. Wunz, N. E. MacKenzie, P. R. Gooley, and W. A. Remers. Computer simulation of the binding of naphthyridinomycin and cyanocycline A to DNA. J. Med. Chem. 34:2079-2088 (1991).
67. S. M. Cutts, A. Nudelman, A. Rephaeli, and D. R. Phillips. The power and potential of doxorubicin-DNA adducts. IUBMB Life. 57:73-81 (2005).
68. M. A. Moufarij, S. M. Cutts, G. M. Neumann, K. Kimura, and D. R. Phillips. Barminomycin functions as a potent pre-activated analogue of adriamycin. Chem. Biol. Interact. 138:137-153 (2001).
69. D. E. Williams, R. L. Reed, B. Kedzierski, G. A. Dannan, F. P. Guengerich, and D. R. Buhler. Bioactivation and detoxication of the pyrrolizidine alkaloid senecionine by cytochrome P-450 enzymes in rat liver. Drug Metab. Dispos. 17:387-392 (1989).
70. Pyrrolizidine Alkaloids. In International Programme on Chemical Safety I, (ed.), Environmental Health Criteria. Vol 80: UN Environment Programme, International Labour Organization, WHO, 1988.
71. S. Kumar, K. Kassahun, R. A. Tschirret-Guth, K. Mitra, and T. A. Baillie. Minimizing metabolic activation during pharmaceutical lead optimization: Progress, knowledge gaps and future directions. Curr. Opin. Drug Discov. Devel. 11:43-52 (2008).
72. N. A. Thornberry, and A. E. Weber. Discovery of JANUVIA (Sitagliptin), a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Curr. Top Med. Chem. 7:557-568 (2007).
73. R. C. Garner, C. N. Martin, and D. B. Clayson. Carcinogenic aromatic amines and related compounds. In C. E. Searle (ed.), Chemical Carcinogens, Vol 1, American Chemical Society, Washington, DC, USA, 1982, pp. 175-276.
74. C. R. Jones, and G. Sabbioni. Identification of DNA adducts using HPLC/ MS/MS following in vitro and in vivo experiments with arylamines and nitroarenes. Chem. Res. Toxicol. 16:1251-1263 (2003).
75. X. Chen, A. Christopher, J. P. Jones, et al. Crystal structure of the F87W/Y96F/V247L mutant of cytochrome P-450cam with 1,3,5-trichlorobenzene bound and further protein engineering for the oxidation of pentachlorobenzene and hexachlorobenzene. J. Biol. Chem. 277:37519-37526 (2002).
76. S. J. Roffey, S. Cole, P. Comby, et al. The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human. Drug Metab. Dispos. 31:731-741 (2003).
77. H. Chen, J. Shockcor, W. Chen, R. Espina, L. S. Gan, and A. E. Mutlib. Delineating novel metabolic pathways of DPC 963, a non-nucleoside reverse transcriptase inhibitor, in rats. Characterization of glutathione conjugates of postulated oxirene and benzoquinone imine intermediates by LC/MS and LC/NMR. Chem. Res. Toxicol. 15:388-399 (2002).
78. D. K. Dalvie, A. S. Kalgutkar, S. C. Khojasteh-Bakht, R. S. Obach, J. P. O, and Donnell. Biotransformation reactions of five-membered aromatic heterocyclic rings. Chem. Res. Toxicol. 15:269-299 (2002).
79. K. L. Kunze, W. L. Nelson, E. D. Kharasch, K. E. Thummel, and N. Isoherranen. Stereochemical aspects of itraconazole metabolism in vitro and in vivo. Drug Metab. Dispos. 34:583-590 (2006).
80. J. T. Pearson, J. J. Hill, J. Swank, N. Isoherranen, K. L. Kunze, and W. M. Atkins. Surface plasmon resonance analysis of antifungal azoles binding to CYP3A4 with kinetic resolution of multiple binding orientations. Biochemistry. 45:6341-6353 (2006).
81. C. W. Locuson, J. M. Hutzler, and T. S. Tracy. Visible spectra of type II cytochrome P450-drug complexes: Evidence that "incomplete" heme coordination is common. Drug Metab. Dispos. 35:614-622 (2007).
82. J. M. Hutzler, R. C. Steenwyk, E. B. Smith, G. S. Walker, and L. C. Wienkers. Mechanism-based inactivation of cytochrome P450 2D6 by 1-[(2-ethyl-4-methyl-1H-imidazol-5-yl)methyl]-4-[4-(trifluoromethyl)-2- pyridinyl]piperazine: Kinetic characterization and evidence for apoprotein adduction. Chem. Res. Toxicol. 17:174-184 (2004).
83. T. J. Monks, and D. C. Jones. The metabolism and toxicity of quinones, quinonimines, quinone methides, and quinone-thioethers. Curr. Drug Metab. 3:425-438 (2002).
84. B. Kalyanaraman, P. I. Premovic, and R. C. Sealy. Semiquinone anion radicals from addition of amino acids, peptides, and proteins to quinones derived from oxidation of catechols and catecholamines. An ESR spin stabilization study. J. Biol. Chem. 262:11080-11087 (1987).
85. S. S. Lau, B. A. Hill, R. J. Highet, and T. J. Monks. Sequential oxidation and glutathione addition to 1,4-benzoquinone: Correlation of toxicity with increased glutathione substitution. Mol. Pharmacol. 34:829-836 (1988).
86. K. G. Eckert, P. Eyer, J. Sonnenbichler, and I. Zetl. Activation and detoxication of aminophenols. III. Synthesis and structural elucidation of various glutathione addition products to 1,4-benzoquinone. Xenobiotica. 20:351-361 (1990).
87. P. E. Weller, and R. P. Hanzlik. Isolation of S-(bromophenyl)cysteine isomers from liver proteins of bromobenzene-treated rats. Chem. Res. Toxicol. 4:17-20 (1991).
88. T. J. Monks, R. P. Hanzlik, G. M. Cohen, D. Ross, and D. G. Graham. Quinone chemistry and toxicity. Toxicol. Appl. Pharmacol. 112:2-16 (1992).
89. A. Chenna, B. Hang, B. Rydberg, et al. The benzene metabolite p-benzoquinone forms adducts with DNA bases that are excised by a repair activity from human cells that differs from an ethenoadenine glycosylase. Proc. Natl. Acad. Sci. U. S. A. 92:5890-5894 (1995).
90. Q. Zhou, and S. E. Rokita. A general strategy for target-promoted alkylation in biological systems. Proc. Natl. Acad. Sci. U. S. A. 100:15452-15457 (2003).
91. T. Atsumi, S. Fujisawa, and K. Tonosaki. A comparative study of the antioxidant/prooxidant activities of eugenol and isoeugenol with various concentrations and oxidation conditions. Toxicol. In Vitro. 19:1025-1033 (2005).
92. W. G. Lai, N. Zahid, and J. P. Uetrecht. Metabolism of trimethoprim to a reactive iminoquinone methide by activated human neutrophils and hepatic microsomes. J. Pharmacol. Exp. Ther. 291:292-299 (1999).
93. R. Singh, M. V. Silva Elipe, P. G. Pearson, et al. Metabolic activation of a pyrazinone-containing thrombin inhibitor. Evidence for novel biotransformation involving pyrazinone ring oxidation, rearrangement, and covalent binding to proteins. Chem. Res. Toxicol. 16:198-207 (2003).
94. W. Bicker, M. Lammerhofer, D. Genser, H. Kiss, and W. Lindner. A case study of acute human chlorpyrifos poisoning: Novel aspects on metabolism and toxicokinetics derived from liquid chromatography-tandem mass spectrometry analysis of urine samples. Toxicol. Lett. 159:235-251 (2005).
95. K. A. Koeplinger, Z. Zhao, T. Peterson, et al. Activated sulfonamides are cleaved by glutathione-S-transferases. Drug Metab. Dispos. 27:986-991 (1999).
96. Z. Zhao, K. A. Koeplinger, T. Peterson, et al. Mechanism, structure-activity studies, and potential applications of glutathione S-transferase-catalyzed cleavage of sulfonamides. Drug Metab. Dispos. 27:992-998 (1999).
97. C. W. Conroy, H. Schwam, and T. H. Maren. The nonenzymatic displacement of the sulfamoyl group from different classes of aromatic compounds by glutathione and cysteine. Drug Metab. Dispos. 12:614-618 (1984).
98. M. Fukuoka, M. Satoh, and A. Tanaka. Metabolism of 2-thiobenzothiazoles in the rat. Urinary, fecal and biliary metabolites of 2-benzothiazyl sulfenamides. Arch. Toxicol. 70:1-9 (1995).
99. X. Chen, and W. Wang. The use of bioisosteric groups in lead optimization. In M. Desai (ed.), Ann. Rep. Med. Chem. Vol 38, American Chemical Society, Washington DC, USA, 2003, pp. 333-346.
100. M. J. Bailey, and R. G. Dickinson. Acyl glucuronide reactivity in perspective: Biological consequences. Chem. Biol. Interact. 145:117-137 (2003).
101. R. J. Herr. 5-Substituted-1H-tetrazoles as carboxylic acid isosteres: medicinal chemistry and synthetic methods. Bioorg. Med. Chem. 10:3379-3393 (2002).
102. M. Gallant, M. C. Carriere, A. Chateauneuf, et al. Structure-activity relationship of biaryl acylsulfonamide analogues on the human EP(3) prostanoid receptor. Bioorg. Med. Chem. Lett. 12:2583-2586 (2002).
103. D. E. Uehling, K. H. Donaldson, D. N. Deaton, et al. Synthesis and evaluation of potent and selective beta(3) adrenergic receptor agonists containing acylsulfonamide, sulfonylsulfonamide, and sulfonylurea carboxylic acid isosteres. J. Med. Chem. 45:567-583 (2002).
104. J. A. Miller. Sulfonation in chemical carcinogenesis - history and present status. Chem. Biol. Interact. 92:329-341 (1994).
105. H. Glatt. Sulfotransferases in the bioactivation of xenobiotics. Chem. Biol. Interact. 129:141-170 (2000).